Justia U.S. Federal Circuit Court of Appeals Opinion Summaries

by
The United States Court of Appeals for the Federal Circuit affirmed the decisions from the United States Patent and Trademark Office, Patent Trial and Appeal Board in a patent dispute between Pacific Biosciences of California, Inc. (PacBio) and Personal Genomics Taiwan, Inc. (PGI). The core dispute revolved around the interpretation of the term "identifying a single biomolecule" in the claims of PGI’s U.S. Patent No. 7,767,441. The Board interpreted the term to mean that the apparatus must be capable of ascertaining the identity of one single, individual biomolecule by examining only that biomolecule. On appeal, the court affirmed the Board’s interpretation. PacBio challenged the Board’s finding that the Hassibi reference did not disclose “identifying a single biomolecule” under the claim construction, while PGI challenged the Board’s finding that the Choumane reference did disclose “identifying a single biomolecule” under that construction. The court found substantial evidence supporting the Board’s findings for both references and affirmed the decisions. PacBio and PGI bear their own costs. View "PACIFIC BIOSCIENCES OF CALIFORNIA, INC. v. PERSONAL GENOMICS TAIWAN, INC. " on Justia Law

by
In this case, the United States Court of Appeals for the Federal Circuit ruled against Philadelphia Energy Solutions Refining and Marketing, LLC ("Philadelphia Energy"). Philadelphia Energy, a fuel producer, had appealed a decision by the United States Court of Federal Claims denying their claim for tax refunds for excise taxes they had paid on fuel mixtures of butane and gasoline. Philadelphia Energy argued that these fuel mixtures should be considered "alternative fuel mixtures" under 26 U.S.C. § 6426(e), making them eligible for a tax credit. However, the Court of Appeals upheld the lower court's decision, finding that butane, despite being considered a liquefied petroleum gas, is not considered an "alternative fuel" under this statute. This is because butane is also a "taxable fuel," and the statutory language creates a dichotomy between "taxable fuels" and "special motor fuels", with the two being mutually exclusive. Consequently, Philadelphia Energy's mixture of butane and gasoline does not qualify for the alternative fuel mixture credit, and they are not entitled to the claimed tax refunds. View "PHILADELPHIA ENERGY SOLUTIONS REFINING v. US " on Justia Law

by
This case revolves around an interlocutory appeal from a consolidated case between Abbott Diabetes Care, Inc., Abbott Diabetes Care Sales Corp. (collectively, “Abbott”), and DexCom, Inc. at the United States District Court for the District of Delaware. DexCom had sued Abbott for infringing its patents, leading Abbott to petition for inter partes review of the asserted patents before the Patent Trial and Appeal Board. DexCom sought a preliminary injunction to prevent Abbott from proceeding with the inter partes review proceedings based on a forum selection clause in a settlement and license agreement between the parties. DexCom appealed the district court’s denial of the preliminary injunction.The United States Court of Appeals for the Federal Circuit affirmed the district court's decision, holding that the district court did not abuse its discretion in denying the preliminary injunction. The court found that the forum selection clause in the settlement and license agreement did not preclude the filing of inter partes review petitions after the Covenant Period because it allowed them during the Covenant Period. Therefore, DexCom could not succeed on its breach-of-contract counterclaim, making it ineligible for a preliminary injunction. View "DEXCOM, INC. v. ABBOTT DIABETES CARE, INC. " on Justia Law

by
In the patent infringement case between K-fee System GmbH and Nespresso USA, Inc., the United States Court of Appeals for the Federal Circuit reversed the district court’s decision. K-fee owns three patents related to coffee-machine portion capsules that display information to prevent their use in incompatible machines. The company alleged that Nespresso infringed these patents. The district court had interpreted the term "barcode" in K-fee's patents to exclude "bit codes," or codes made up of two binary symbols. Based on this interpretation, the court granted Nespresso’s motion for summary judgment of non-infringement.On appeal, the Federal Circuit disagreed with the district court’s interpretation of “barcode.” The court found that a "barcode" is defined by its visual appearance as a lineup of bars with varying widths, and that this definition can include bit codes. The court determined that the district court had erred in its claim construction of "barcode," and consequently, in its grant of summary judgment of non-infringement based on that construction. The case was remanded for further proceedings in line with this interpretation. View "K-FEE SYSTEM GMBH v. NESPRESSO USA, INC. " on Justia Law

by
Crispin Torres, a former employee of the Department of Homeland Security's Immigration and Customs Enforcement (ICE), appealed an arbitration decision which upheld his removal from the agency for unauthorized travel and falsification of certified records. The United States Court of Appeals for the Federal Circuit found that the arbitrator did not provide substantial evidence for concluding that two key factors, consistency of penalty with similar offenses (Douglas factor 6) and potential for rehabilitation (Douglas factor 10), weighed in favor of Mr. Torres' removal. The court found that the arbitrator failed to fully consider comparator cases where similar misconduct by other ICE law enforcement officers resulted in suspension rather than removal, and did not adequately explain why Mr. Torres had no potential for rehabilitation. The court vacated the arbitrator's decision and remanded the case for further proceedings consistent with its opinion. View "TORRES v. DHS " on Justia Law

by
The case involves ParkerVision, Inc. appealing a decision by the Patent Trial and Appeal Board (Board) that invalidated one of its patents, U.S. Patent No. 7,110,444 ('444 patent), owned by ParkerVision, Inc., which relates to wireless local area networks (WLANs) that use frequency translation technology. The Board determined that claim 3 of the patent is unpatentable as obvious in light of prior art. The United States Court of Appeals for the Federal Circuit affirmed the Board's decision. The court found that the Board correctly construed the term “storage element” and did not procedurally err in how it treated certain arguments raised by the parties. The court also found substantial evidence supporting the Board's finding that the patent claim was obvious in light of prior art. The court found no violation of ParkerVision's procedural rights under the Administrative Procedure Act (APA) and no abuse of the Board's discretion in excluding parts of ParkerVision’s sur-reply. View "PARKERVISION, INC. v. VIDAL " on Justia Law

by
In 2017, Donald Winkler received a Tdap vaccination after stepping on rusted metal. Soon after, he developed symptoms of Guillain-Barré Syndrome (GBS), a type of acute monophasic peripheral neuropathy. Winkler filed a petition for relief under the National Vaccine Injury Compensation Program, asserting the Tdap vaccine caused his GBS. However, the Special Master denied his claim, and this decision was upheld by the United States Court of Federal Claims. Winkler appealed to the United States Court of Appeals for the Federal Circuit.The appellate court affirmed the lower court's decision. The court noted that GBS is not listed as a covered condition for Tdap vaccines, so Winkler had to prove that his GBS was actually caused by the Tdap vaccination. The court applied the three-prong test set forth in Althen v. Secretary of Health and Human Services, requiring Winkler to show a medical theory causally connecting the vaccination and the injury, a logical sequence of cause and effect showing that the vaccination was the reason for the injury, and a proximate temporal relationship between vaccination and injury.The Special Master found that Winkler had not established the second Althen prong, as he failed to provide preponderant evidence of a logical sequence of cause and effect. The court disagreed with Winkler's argument that the Special Master erred by requiring him to disprove that he suffered from a Campylobacter jejuni infection, a known trigger for GBS, stating that Winkler mischaracterized his burden of proof. The court further stated that Winkler failed to establish a prima facie case of causation of his GBS by the Tdap vaccine, not that he failed to disprove evidence of an infection. Therefore, the court affirmed the Special Master's holding that Winkler failed to prove causation of GBS by the Tdap vaccine by preponderant evidence. View "WINKLER v. HHS " on Justia Law

Posted in: Health Law
by
In this case, Nova Group/Tutor-Saliba (“NTS”) was awarded a construction contract by the United States Department of the Navy to build a new aircraft carrier maintenance pier at a naval base. The contract required NTS to demolish an old pier, design and build a replacement pier, and construct a new structure known as the Mole Quaywall, which would be designed by the government. During construction, NTS encountered unexpected subsurface soil conditions that complicated and increased the cost of the project. NTS sought additional compensation from the government alleging differing site conditions.The United States Court of Appeals for the Federal Circuit affirmed the decision of the United States Court of Federal Claims which had denied NTS's claim for additional compensation. The Court of Federal Claims found that NTS had not established a Type I differing site condition because the contract documents disclosed that NTS would encounter unpredictable subsurface conditions and possible obstructions. It also found that NTS had failed to prove a Type II differing site condition, as it had not demonstrated that any of the potential causes for hard driving were unknown or unusual in the region or materially different from comparable work. The Court of Appeals agreed with these findings and also ruled that the parol evidence rule had not been violated as NTS claimed. The Court of Appeals found that the parol evidence rule does not prevent a party from presenting evidence that a recital of fact in an integrated agreement may be untrue, and the challenged evidence was not introduced to modify any term of the contract. Therefore, the appeal by NTS was denied and the decision of the Court of Federal Claims was affirmed. View "NOVA GROUP/TUTOR-SALIBA v. US " on Justia Law

by
In this case, the United States Court of Appeals for the Federal Circuit considered whether the defendants' Abbreviated New Drug Applications (ANDAs) infringed two patents owned by the plaintiffs. The patents pertained to the use of the drug vortioxetine in the treatment of patients who had previously taken certain other antidepressant medications and had to cease or reduce use due to sexually related adverse events, and for the treatment of cognitive impairment. The defendants were seeking approval to market vortioxetine for the treatment of Major Depressive Disorder (MDD) in adults, a use not covered by the patents. The plaintiffs sought to block the defendants from marketing a generic version of the drug until after the expiration of the patents.The court held that the defendants' ANDA filings did not infringe the plaintiffs' patents. The court found that the defendants' intended use of the drug, for the treatment of MDD in adults, did not infringe the patents which pertained to other specific uses of the drug.Moreover, the court found no induced or contributory infringement. Regarding induced infringement, the court held that the defendants' proposed labels for the drug did not encourage, recommend, or promote an infringing use. Regarding contributory infringement, the court held that the defendants' sale of the drug would have substantial noninfringing uses, thus there would be no contributory infringement.Additionally, the court rejected Lupin's cross-appeal, which challenged the district court's determination that Lupin infringed a patent concerning a process for manufacturing vortioxetine. The court affirmed the district court's construction of the term "reacting" in the patent and its determination of infringement. View "H. LUNDBECK A/S v. LUPIN LTD. " on Justia Law

by
The case involves the classification of certain knit gloves with partial plastic coating under the Harmonized Tariff Schedule of the United States. The United States Court of Appeals for the Federal Circuit affirmed the decision of the United States Court of International Trade that the gloves are properly classified under heading 6116. The plaintiff, Magid Glove & Safety Manufacturing Co. LLC, imported the gloves from China and South Korea and argued that the gloves should have been classified under subheading 3926.20.10, a duty-free provision. However, the Court of International Trade and the Court of Appeals disagreed, stating that the gloves are not "of plastics" as required by heading 3926, but are "knitted" as described by heading 6116. The Court of Appeals also rejected the plaintiff's argument that Section XI Note 1(h) and the "completely embedded" test applied in a previous case excluded the gloves from classification under heading 6116. The court concluded that the term "completely embedded" does not appear in Section XI Note 1(h) or the two competing headings in this case and is not applicable to the classification of the gloves. View "MAGID GLOVE & SAFETY MANUFACTURING CO. LLC v. US" on Justia Law